ALK and neuroblastoma: Validation of the immunoassays is presented using a panel of neuroblastoma cell lines and evidence of on‐target ALK inhibition provided by treatment of a genetically engineered murine model of neuroblastoma with two clinical ALK inhibitors, crizotinib and ceritinib, highlighting the superior efficacy of ceritinib.